Throughout this medical market research, the publisher analyzed 43 cardiac surgery companies companies in the US and utilized their comprehensive methodology to understand the Market Sizes, Unit Sales, ASPs, Company Market Shares, and to create accurate forecasts.
While this MedSuite report contains all of the US Cardiac Surgery Device and Heart Valve Device market analysis, each of the market segments is also available as stand-alone MedCore reports. Additionally, this research includes an interventional cardiology procedure volume analysis which can also be purchased as a separate report, MedPro.
Markets Covered
US Cardiac Surgery Device Market Insights
A major limiter to the cardiac surgery market is the limited clinical data available for some of the newer markets. Growth in the cerebral embolic protection (CEPD) market may be limited until a large randomized clinical trial is conducted to determine the device’s exact role in reducing cerebral ischemic volumes. The CEPD market has experienced strong growth in recent years but may be unable to reach its full market potential without this additional clinical data.
A major driver in the cardiac surgery market is the patient population, which is large for many of the indications for cardiac surgery devices. Approximately 1.2 million people in the U.S. have calcified or otherwise damaged aortic valves. This condition is typically present in patients who have several other co-morbidities, making them poor candidates for open, invasive surgery.
Overall, the U.S. cardiac surgery and heart valve device market was valued at $7.2 billion in 2019. This is expected to increase over the forecast period at a CAGR of 7.7% to reach $12.1 billion.
While this MedSuite report contains all of the US Cardiac Surgery Device and Heart Valve Device market analysis, each of the market segments is also available as stand-alone MedCore reports. Additionally, this research includes an interventional cardiology procedure volume analysis which can also be purchased as a separate report, MedPro.
Markets Covered
- Procedure Volumes for the US Cardiac Surgery Market - MedPro
- Tissue Heart Valve Market - MedCore
- Mechanical Heart Valve Market - MedCore
- Annuloplasty Repair Device Market - MedCore
- Transcatheter Mitral Valve Repair Device Market - MedCore
- Transcatheter Heart Valve Replacement Market - MedCore
- Cerebral Embolic Protection Device Market - MedCore
- Balloon Valvuloplasty Market - MedCore
- On-Pump Coronary Artery Bypass Device Market - MedCore
- Off-Pump Coronary Artery Bypass Device Market - MedCore
- Autotransfusion Device Market - MedCore
- Endoscopic Vessel Harvesting Device Market - MedCore
- Anastomosis Assist Device (AAD) Market - MedCore
- Transmyocardial Revascularization Market - MedCore
- Ventricular Assist Device (VAD) Market - MedCore
- Intra-Aortic Balloon Pump Market - MedCore
- Artificial Heart Replacement Device Market - MedCore
- Remote Hemodynamic Monitoring System Market - MedCore
- Patent Foramen Ovale Closure Device Market - MedCore
- Patent Ductus Arteriosus Closure Device Market - MedCore
- Atrial Septal & Ventricular Septal Defect Closure Device Marke - MedCore
- Left Atrial Appendage Closure Device Market - MedCore
- Preshaped Guidewire Market - MedCore
- Extracorporeal Membrane Oxygenation Market - MedCore
US Cardiac Surgery Device Market Insights
A major limiter to the cardiac surgery market is the limited clinical data available for some of the newer markets. Growth in the cerebral embolic protection (CEPD) market may be limited until a large randomized clinical trial is conducted to determine the device’s exact role in reducing cerebral ischemic volumes. The CEPD market has experienced strong growth in recent years but may be unable to reach its full market potential without this additional clinical data.
A major driver in the cardiac surgery market is the patient population, which is large for many of the indications for cardiac surgery devices. Approximately 1.2 million people in the U.S. have calcified or otherwise damaged aortic valves. This condition is typically present in patients who have several other co-morbidities, making them poor candidates for open, invasive surgery.
Overall, the U.S. cardiac surgery and heart valve device market was valued at $7.2 billion in 2019. This is expected to increase over the forecast period at a CAGR of 7.7% to reach $12.1 billion.
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Abbott
- Abiomed
- Angel Valve Vienna
- AtriCure
- B. Braun
- Becton Dickinson
- Berlin Heart
- Biostable
- Blue Sail
- Boston Scientific
- Cardia
- Cardiac Dimensions
- Cardio Mech
- CARMAT
- Chase Medical
- Colibri Heart Valve
- Cook Medical
- CoreMedic
- CryoLife
- Edwards Lifesciences
- Genesee Biomedical
- Getinge
- Gore
- JenaValve
- Karl Storz
- LifeNet Health
- LivaNova
- Medtronic
- Meril Life Sciences
- Mitralign
- NeoChord
- Occlutech
- Peters Surgical
- PFM Medical
- Saphena Medical
- SentreHeart
- SynCardia
- TandemLife
- Teleflex
- Terumo
- Thubrikar Aortic Valve
- Toray
- Venus Medtech
